ReviewCancers2019
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 52 citations in OpenAlex.
- Current review of pediatric Fas-associated death domain protein deficiency: expanding clinical and therapeutic perspectives.Clinical and experimental pediatrics · 2026Article
- Leveraging the htsFLT01/MiRGD Complex to Enhance Apoptosis and Suppress Angiogenesis in MCF7 Breast Cancer Cells.Iranian journal of medical sciences · 2025Article
- Evaluation of the Apoptotic, Prooxidative and Therapeutic Effects of Odoroside A on Lung Cancer: An In Vitro Study Extended with In Silico Analyses of Human Lung Cancer Datasets.Life (Basel, Switzerland) · 2025Article
- Exploring Mechanisms and Biomarkers of Breast Cancer Invasion and Migration: An Explainable Gene-Pathway-Compounds Neural Network.Cancer medicine · 2025Article
- Significance of novel PANoptosis genes to predict prognosis and therapy effect in the lung adenocarcinoma.Scientific reports · 2024Article
- Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma.BJC reports · 2024Article
- A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.International journal of molecular sciences · 2024Article
- Deciphering COPS5 influence on immune infiltration and prognosis in head and neck squamous cell carcinoma.Heliyon · 2024Article
- Identification and analysis of prognostic immune cell homeostasis characteristics in lung adenocarcinoma.The clinical respiratory journal · 2024Article
- Cellular Dynamics of Fas-Associated Death Domain in the Regulation of Cancer and Inflammation.International journal of molecular sciences · 2024Review
- The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis.Biomedical reports · 2023Article
- Identifying prognostic genes related PANoptosis in lung adenocarcinoma and developing prediction model based on bioinformatics analysis.Scientific reports · 2023Article
- Article
- Review
- Molecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit fromFrontiers in neuroscience · 2023Article
- Metabolic genes, a potential predictor of prognosis and immunogenicity of clear cell renal cell carcinoma.American journal of cancer research · 2023Article
- Apoptosis-mediated inhibition of human T-cell acute lymphoblastic leukemia upon treatment withFrontiers in immunology · 2023Article
- Upregulated FADD is associated with poor prognosis, immune exhaustion, tumor malignancy, and immunotherapy resistance in patients with lung adenocarcinoma.Frontiers in oncology · 2023Article
- FADD as a key molecular player in cancer progression.Molecular medicine (Cambridge, Mass.) · 2022Review
- Identification of autophagy-related biomarker and analysis of immune infiltrates in oral carcinoma.Journal of clinical laboratory analysis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
FADD was initially described as an adaptor molecule for death receptor-mediated apoptosis, but subsequently it has been implicated in nonapoptotic cellular processes such as proliferation and cell cycle control. During the last decade, FADD has been shown to play a pivotal role in most of the signalosome complexes, such as the necroptosome and the inflammasome. Interestingly, various mechanisms involved in regulating FADD functions have been identified, essentially posttranslational modifications and secretion. All these aspects have been thoroughly addressed in previous reviews. However, FADD implication in cancer is complex, due to pleiotropic effects. It has been reported either as anti- or protumorigenic, depending on the cell type. Regulation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.